SlideServe
Menu
Préférences
© SlideServe · v2026

Prostate Cancer

avye-pugh avatar
20 diapositives · 869 Views · Nov 03, 2014

Prostate Cancer. Objectives. The learner will be able to: Identify diagnostic methods for determining the presence and stage of prostate cancer. Describe possible treatment modalities for prostate cancer. Discuss nursing implications for a patient newly diagnosed with prostate cancer.

Prostate Cancer - slide 1
01 / 20Prostate Cancer
1 / 17

Télécharger la présentation

Prostate Cancer
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation

Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement. Téléchargez la présentation en cliquant sur ce lien. Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.

F I N

Plus de contenu associé

Transcription de la présentation
  1. Prostate Cancer

  2. Objectives The learner will be able to: • Identify diagnostic methods for determining the presence and stage of prostate cancer. • Describe possible treatment modalities for prostate cancer. • Discuss nursing implications for a patient newly diagnosed with prostate cancer.

  3. Epidemiology • 6 in 10 men are 65 and >; average age at diagnosis is 66 • African American • First-degree relative with prostate cancer • Genetics • BRCA1 and BRCA2 genes • HPC1 gene • 1 out of 7 men will be diagnosed in their lifetime with prostate cancer

  4. Screening • African Americans or first-degree relative • Annual digital rectal exam (DRE) • Annual prostate specific antigen (PSA) blood test • Controversial • May reveal clinically insignificant tumors • Treatment of insignificant tumors • Adverse side effects • Diminished quality of life

  5. Diagnostics • DRE • Elevated PSA • Transrectal ultrasound (TRUS) • Biopsy (often combined with TRUS) • Pelvic magnetic resonance imaging (MRI) • Bone scan

  6. Gleason Score • Biopsy samples examined under microscope • The most common cell type is graded and the second most common cell type is graded. • Well-differentiated (1) • Moderately differentiated (2) • Poorly differentiated (34) • Not recognized as prostate cell (5) • These two numbers are added together.

  7. Staging • Stage I • Involves small area of prostate gland • Stage II • Confined to prostate gland, but may involve both lobes • Stage III • Extends outside prostate capsule • Stage IV • Involves structures adjacent to the prostate

  8. Treatment Options • “Watchful waiting” • Surgical removal of the prostate (prostatectomy) • Radiation therapy • External beam • Brachytherapy • Cryosurgery • Pharmacotherapy

  9. “Watchful Waiting” • For localized, low-grade tumors • DRE determines if prostate is enlarging. • Rapid PSA elevation may indicate a more aggressive cell type. • Rate of change determines if the client can continue to be monitored or if more aggressive treatment should begin.

  10. Trans-Urethral Resection (TURP) • Scope and cauterization through urethra • Removes prostate in pieces • Does not “cure” prostate cancer

  11. Prostatectomy • Surgical removal of prostate • Open incision • Retropubic (lower abdominal incision) • Perineal (incision between scrotum and rectum) • Laparoscopy • Radical prostatectomy • Prostate, seminal vesicles, ejaculatory ducts, lymph node sampling

  12. Postoperative Care • Monitor blood loss. • Maintain catheter patency (NS irrigation). • DO NOT REMOVE CATHETER. • Monitor fluid/electrolyte status. • Provide wound care. • Monitor signs of infection. • Monitor complications of immobility.

  13. Discharge Education • Indwelling catheter care • Maintain fluid intake 2 L/day. • Walk 46 times/day; encourage deep breathing exercises/use of incentive spirometer • Report fever or chills. • Report leg pain or edema. • Report bright red urine, multiple clots, decreased urine production.

  14. Radiation Therapy • External beam • X-rays are delivered through tissues from three angles. • Non-prostate tissues are protected. • Client is not radioactive. • Surgery is not a subsequent option after radiation therapy.

  15. Radiation Therapy (cont.) • Brachytherapy (temporary or permanent) • Needles are inserted through the perineum into prostate. • Radioactive “seeds” are inserted through needles. • Permanent seeds may be lost through urethra (voiding or intercourse). • Client is radioactive. • Surgery is not an option after radiation therapy.

  16. Cryosurgery • Probes are inserted through skin into prostate. • Gas is delivered through probe, which freezes local tissue. • Urethra is protected by circulating warm water. • Reserved for small tumors • May need to be repeated

  17. Pharmacotherapy • Hormone-blocking therapy • Estrogen • Ketoconazole • Leutinizing hormone-releasing hormone (LHRH) • Leuprolide • Goserelin • Chemotherapy

  18. Long-Term Complications • Urinary incontinence • Sexual dysfunction • Bladder outlet obstruction • Leg and scrotal edema • Pain (metastasis to bone)

  19. References American Cancer Society. (2014). Cancer facts and figures 2014. Atlanta, GA: Author. American Cancer Society. (2013). American Cancer Society guidelines for the early detection of cancer: Prostate. Retrieved from http://www.cancer.org/Healthy/FindCancerEarly/CancerScreeningGuidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer Brawley, O.W., & Barnes, S. (2001). The epidemiology of prostate cancer in the United States. Seminars in Oncology Nursing, 17, 7277. Cooney, K.A., McCarthy, J.D., Lange, E., Huang, L., Miesfeldt, S., Montie, J.E., … Lange, K. (1997). Prostate cancer susceptibility locus on chromosome 1q: A confirmatory study. Journal of the National Cancer Institute, 89, 955 959. Ekman, P. (1999). Genetic and environmental factors in prostate cancer genesis: Identifying high-risk cohorts. European Urology, 35, 362369.

  20. References (cont.) Greene, F.L., Page, D.L., Fleming, I.D., Fritz, A., Balch, C.M., Haller, D.G., & Morrow, M. (Eds.). (2002). AJCC cancer staging manual (6th ed.). New York, NY: Springer-Verlag. Held-Warmkessel, J. (2005). Prostate cancer. In C.H. Yarbro, M.H. Frogge, & M. Goodman (Eds.), Cancer nursing: Principles and practice (6th ed., pp. 15521580). Sudbury, MA: Jones and Bartlett. O’Rourke, M.E. (2006). Nursing care of the client with cancers of the urinary system. In J.K. Itano & K.N. Taoka (Eds.), Core curriculum for oncology nursing (4th ed., pp. 584614). St. Louis, MO: Elsevier Saunders. Scott, R., Mutchnik, D.L., Laskowski, T.Z., & Schmallhorst, W.R. (1969). Carcinoma of the prostate in elderly men: Incidence, growth characteristics and clinical significance. Journal of Urology, 101, 602607. Stroller, M.L., & Carroll, P.R. (2003). Urology. In L.M. Tierney, S.J. McPhee, & M.A. Papadakis (Eds.), CMDT: Current medical diagnosis and treatment. (42nd ed., pp. 903945). New York, NY: Lange Medical Books/McGraw-Hill.